In addition, it was demonstrated that 20% of AML patients had mutations in the metabolic enzyme isocitrate dehydrogenase (IDH), which is involved in a variety of metabolic and epigenetic cellular processes, including lipid metabolism alterations, and whose alterations may differentially affect prognosis [75,76]. The gene discussed is IDH1; the disease is acute myeloid leukemia.